Imaging in neuroblastoma: An update

Seema A Kembhavi; Sneha Shah; Venkatesh Rangarajan; Sajid Qureshi; Palak Popat; Purna Kurkure

doi:10.4103/0971-3026.155844

Indian Journal of Radiology and Imaging, Table of Contents

CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2015; 25(02): 129-136
DOI: 10.4103/0971-3026.155844

Imaging in Oncology: Recent Advances

Imaging in neuroblastoma: An update

Seema A Kembhavi

Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Sneha Shah

Department of Bio-imaging, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Venkatesh Rangarajan

Department of Bio-imaging, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Sajid Qureshi

Department of Surgery, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Palak Popat

Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Purna Kurkure

Department of Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

› Author Affiliations

Abstract

PDF Download

Abstract

Neuroblastoma is the third common tumor in children. Imaging plays an important role in the diagnosis, staging, treatment planning, response evaluation and in follow-up of a case of Neuroblastoma. The International Neuroblastoma Risk Group task force has recently introduced an imaging-based staging system and laid down guidelines for uniform reporting of imaging studies. This review is an update on imaging in neuroblastoma, with emphasis on these guidelines.

Keywords

Image-defined risk factor - international neuroblastoma risk group staging system - metaiodobenzylguanidine - neuroblastoma

PDF (1590 kb)

References

References
1 Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by (123) I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319-26.
2 Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 2009;27:289-97.
3 Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 2009;27:298-303.
4 Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, et al.; International Neuroblastoma Risk Group Project. Guidelines for imaging and staging of neuroblastic tumours: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243-57.
5 Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278-92.
6 Kushner BH, Gilbert F, Helson L. Familial neuroblastoma: Case reports, literature review, and etiologic considerations. Cancer 1986;57:1887-93.
7 Russel HV, Pappo AS, Nuchtern JG, Kornguth DG, Wang LL. Solid tumours of childhood. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman and Rosenberg′s Cancer: Principles and Practice of Oncology. 8 th ed.: Lippincott Williams and Wilkins; 2008. p. 2043-84.
8 Papaioannou G, McHugh K. Neuroblastoma in childhood: Review and radiological findings. Cancer Imaging 2005;5:116-27.
9 Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997;80:2321-32.
10 Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
11 Sawada T, Hirayama M, Nakata T, Takeda T, Takasugi N, Mori T, et al. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet 1984;2:271-3.
12 Sawada T, Kidowaki T, Sakamoto I, Hashida T, Matsumura T, Nakagawa M, et al. Neuroblastoma. Mass screening for early detection and its prognosis. Cancer 1984;53:2731-5.
13 Nishi M, Miyake H, Takeda T, Kikuchi Y, Hanai J, Yonemori H, et al. Mass screening of neuroblastoma in Sapporo City, Japan. Am J Pediatr Hematol Oncol 1992;14:327-31.
14 Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041-6.
15 Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047-53.
16 Scott DJ, Wallace WH, Hendry GM. With advances in medical imaging can the radiologist reliably diagnose Wilms′ tumours? Clin Radiol 1999;54:321-7.
17 Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
18 Salmi D, Patel C, Imashuku S, Shimada H, Satake N. Neuroblastoma of unknown primary site with periorbital bone metastasis in a child. Pediatr Blood Cancer 2010;55:361-3.
19 Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Radiologic-pathologic correlation. Radiographics 2002;22:911-34.
20 Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, et al. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol 2014;32:1228-35.
21 Kushner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 2004;4:1172-88.
22 Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al.; European Association for Nuclear Medicine. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-46.
23 Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumours. J Nucl Med 1994;35:1753-7.
24 Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008;190:1085-90.
25 Ady N, Zucker JM, Asselain B, Edeline V, Bonnin F, Michon J, et al. A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A: 256-61.
26 Messina JA, Cheng SC, Franc BL, Charron M, Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74.
27 Howman-Giles RB, Gilday DL, Ash JM. Radionuclide skeletal survey in neuroblastoma. Radiology 1979;131:497-502.
28 Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
29 Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009;50:1237-43.
30 Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, et al. ¹² 3 I-MIBG scintigraphy/SPECT versus 18 F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011;38:1648-58.
31 O′Dorisio MS, Chen F, O′Dorisio TM, Wray D, Qualman SJ. Characterization of somatostatin receptors on human neuroblastoma tumours. Cell Growth Differ 1994;5:1-8.
32 Albers AR, O′Dorisio MS, Balster DA, Caprara M, Gosh P, Chen F, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000;88:61-73.
33 Schilling FH, Bihl H, Jacobsson H, Ambros PF, Martinsson T, Borgström P, et al. Combined (111) In-pentetreotide scintigraphy and (123) I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000;35:688-91.
34 Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the Children′s oncology group. J Nucl Med 2013;54:541-8.
35 Raggi CC, Maggi M, Renzi D, Calabrò A, Bagnoni ML, Scaruffi P, et al. Quantitative determination of sst2 gene expression in neuroblastoma tumour predicts patient outcome. J Clin Endocrinol Metab 2000;85:3866-73.